Recurrent Depressive Disorder
9
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
11%
1 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Mental Health Associations With Vitiligo
Recovery in Telling Life Stories
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
OSU6162 as add-on in SSRI/SNRI-resistant Depression
Improving Work Outcome for People With Severe Mental Illness
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Ketamine for Relapse Prevention in Recurrent Depressive Disorder
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine